Cart
Orders
Not available hereProduct Overview
Aesplla is a Poly-L-Lactic Acid (PLLA) dermal filler presented as a dry powder in a single vial. The documented 365 mg presentation contains 150 mg PLLA, alongside sodium carboxymethylcellulose and mannitol. PRP Science Co., Ltd. is identified as the manufacturer in Argentine product labeling, with finished-product manufacture documented in South Korea. For professional buyers comparing filler formulations, the important distinction is that 365 mg describes the total powder mass—not the amount of PLLA.
Specifications below describe the documented Aesplla presentation. Confirm the supplied package, market-specific labeling and manufacturer reference before procurement.
Key Features
- PLLA formulation: A Poly-L-Lactic Acid dermal filler, rather than a hyaluronic acid gel filler.
- Defined polymer content: The documented formulation contains 150 mg PLLA per vial.
- Single-vial presentation: The official product listing specifies 365 mg total powder × 1 vial.
- Dry formulation: Supplied as powder, not as a ready-to-use liquid filler.
Composition & Specifications
| Specification | Details |
|---|---|
| Product category | PLLA-based dermal filler |
| Formulation | Dry powder |
| Poly-L-Lactic Acid (PLLA) | 150 mg/vial |
| Sodium carboxymethylcellulose | 90 mg/vial |
| Mannitol | 125 mg/vial |
| Total powder mass | 365 mg/vial |
| Packaging | 1 vial |
| Lidocaine declaration | Not listed in the documented dry-vial composition |
| Manufacturer | PRP Science Co., Ltd., as identified in Argentine labeling |
| Country of origin | South Korea |
Composition amounts refer to the dry vial, not to a liquid concentration or supplied liquid volume.
Storage & Handling
Follow the storage conditions and expiry date on the supplied market-specific package and instructions for use. Confirm these requirements before arranging storage or transport.
The reviewed labeling identifies the vial as single-use and restricts use to professionals or healthcare institutions. Applicable local purchasing and professional-use requirements must also be checked.
Frequently Asked Questions
Does Aesplla contain 365 mg of PLLA?
No. The documented vial contains 365 mg of total powder, comprising 150 mg PLLA, 90 mg sodium carboxymethylcellulose and 125 mg mannitol.
Is lidocaine included in the vial?
Lidocaine is not declared in the documented three-component dry-vial composition. Check the exact supplied package before relying on its lidocaine status for procurement.
What should professional buyers confirm before procurement?
Confirm the manufacturer reference, single-vial presentation, market-specific instructions, storage requirements and expiry date. Regulatory authorization and purchasing eligibility must be assessed for the destination country; this description does not establish permission to purchase or use Aesplla in every market.